My HIMS Hot Take
Earlier this week, pharmaceutical giant Novo Nordisk (NVO) abruptly bailed on its landmark deal with Hims & Hers — even though it’s been less than two months since the deal was first announced. HIMS stock crashed almost 35% on Monday following news that Novo would no longer allow Hims & Hers to sell its popular GLP-1 weight-loss treatment, Wegovy.
Read More